Ipsen is a biopharmaceutical company focused on drug development and commercialization in three therapeutic areas: oncology, rare diseases, and neuroscience. In oncology, the company offers lanreotide, cabozantinib, irinotecan liposome injection, and other products aimed at treating acromegaly, neuroendocrine tumors, metastatic cancers, etc. In rare diseases, it provides odevixibat, elafibranor, and mecasermin for conditions such as Turner syndrome, growth failure in children and adolescents, and primary biliary cholangitis. In neuroscience, Ipsen produces botulinum toxin type A for both therapeutic and aesthetic indications.